Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial

Autor: Meral Esen, Yves Horsmans, Annick Hens, Fernanda Tavares Da Silva, Nathalie Garçon, Frédéric Clement, Isabelle Carletti, Michel Janssens, Geert Leroux-Roels, Laurence Fissette, Robbert van der Most, Jack Levy, Tino F. Schwarz, Wivine Burny, Pascale Van Belle, Philippe Moris, Arnaud Marchant, Edwige Haelterman, Pierre Van Damme, Peter G. Kremsner, Arnaud M. Didierlaurent, Wolfgang Jilg, Marcelle Van Mechelen, Julian J. Gabor
Přispěvatelé: UCL - SSS/IREC-Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN-Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie
Rok vydání: 2016
Předmět:
CD4-Positive T-Lymphocytes
Male
0301 basic medicine
SURFACE-ANTIGEN
HBsAg
medicine.medical_treatment
0302 clinical medicine
FALCIPARUM-MALARIA
Immunologie
Medicine and Health Sciences
CD4(+) T cell
Immunology and Allergy
030212 general & internal medicine
Immunoassay
B-Lymphocytes
Vaccines
MONOPHOSPHORYL-LIPID-A
biology
Immunogenicity
Vaccination
medicine.anatomical_structure
SAFETY
Female
Antibody
Adaptive immune response
Adjuvant
Adult
Memory B cell
Allergie et immunopathologie
CIRCUMSPOROZOITE PROTEIN
T cell
Immunology
Adjuvant system
HERPES-ZOSTER
CD4+ T cell
INDUCE STRONG
03 medical and health sciences
Immune system
Adjuvants
Immunologic
Double-Blind Method
Antigen
medicine
Humans
Hepatitis B Antibodies
Polyfunctionality
Hepatitis B Surface Antigens
Reactogenicity
business.industry
030104 developmental biology
PANDEMIC INFLUENZA VACCINE
Antibody Formation
Luminescent Measurements
Hepatitis B virus surface antigen
biology.protein
Human medicine
CROSS-REACTIVE IMMUNITY
business
SYSTEM
Zdroj: Clinical immunology
Clinical Immunology, Vol. 169, p. 16-27 (2016)
CLINICAL IMMUNOLOGY
Clinical immunology, 169
ISSN: 1521-6616
DOI: 10.1016/j.clim.2016.05.007
Popis: Immunogenicity and safety of different adjuvants combined with a model antigen (HBsAg) were compared. Healthy HBV-naïve adults were randomized to receive HBs adjuvanted with alum or Adjuvant Systems AS01B, AS01E, AS03A or AS04 at Days 0 and 30. Different frequencies of HBs-specific CD4. + T cells 14 days post dose 2 but similar polyfunctionality profiles were induced by the different adjuvants with frequencies significantly higher in the AS01B and AS01E groups than in the other groups. Antibody concentrations 30 days post-dose 2 were significantly higher in AS01B, AS01E and AS03A than in other groups. Limited correlations were observed between HBs-specific CD4. + T cell and antibody responses. Injection site pain was the most common solicited local symptom and was more frequent in AS groups than in alum group. Different adjuvants formulated with the same antigen induced different adaptive immune responses and reactogenicity patterns in healthy naïve adults. The results summary for this study (GSK study number 112115 - NCT
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: